Experimental rhabdoid tumor models have demonstrated significant regression of established tumors under ICB therapy, up to 67% of the mice with the SMARCB1-mutant rhabdomyoma readily responded to anti-PD-1 treatment66. Here, SMARCB1 is linked to rhabdoid tumor.